Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health …
More AMAG Pharmaceuticals’ Q3 Results Overshadowed by Ominous FDA Panel Recommendation Videos